ResearchPod Summary
Developing effective delivery systems for messenger RNA (mRNA) to the central nervous system (CNS) is a major challenge in treating neurological disorders. Existing delivery methods often face barriers such as the blood-brain barrier or limited distribution when injected directly. This study investigates whether custom-designed lipid nanoparticles (LNPs), functionalized with brain-targeting small molecules, can improve the efficiency and distribution of mRNA delivery when administered through an intrathecal injection.
Researchers developed a library of brain-targeting lipids (BLs) by combining amino lipids with brain-targeting small molecules, such as neurotransmitters or neuroprotective agents. By incorporating these lipids into nanoparticle formulations (BLNPs), the team screened for the highest mRNA delivery efficiency using an in vitro neuroblastoma cell line model. The lead candidate, TD5 BLNP, was then evaluated in mice to measure its ability to deliver mRNA to various brain cells (neurons, astrocytes, and microglia) via intrathecal injection. The researchers further assessed the system's ability to facilitate CRISPR-Cas9 genome editing and examined the biocompatibility and safety profile of the formulation.
TD5 BLNPs significantly outperformed standard FDA-approved lipid nanoparticles (DLin-MC3-DMA) in delivering mRNA to the brain. A single intrathecal injection of TD5 BLNP-mRNA resulted in robust protein expression across multiple brain regions, specifically reaching approximately 30% of neurons and 40% of astrocytes. Mechanistic studies indicated that these nanoparticles enter cells primarily through clathrin- and caveolae-mediated endocytosis, with the tryptamine moiety of the TD5 lipid facilitating uptake via 5-HT receptors. Furthermore, the system successfully enabled Cas9 mRNA/sgRNA delivery to induce genome editing in the brain with minimal off-target effects in peripheral organs, all while maintaining a favorable safety profile with low inflammatory responses.
This research provides a powerful, modular platform for delivering therapeutic genetic payloads directly to the CNS. By bypassing systemic circulation and effectively crossing into diverse brain cell populations, this approach offers a promising strategy for treating neurodegenerative diseases, neuroinflammation, or genetic conditions that require localized gene regulation or editing.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.